Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced or metastatic esophageal squamous cell carcinoma (ESCC): PD-L1 biomarker analysis from RATIONALE-306

被引：0
|
作者：
Raymond, E. [1 ]
Xu, J. [2 ]
Kato, K. [3 ]
Hubner, R. [4 ]
Shu, Y. [5 ]
Park, S. R. [6 ]
Kojima, T. [7 ]
Wyrwicz, L. S. [8 ]
Tougeron, D. [9 ]
Geboes, K. [10 ]
Van Cutsem, E. [11 ,12 ]
Pazo Cid, R. A. [13 ]
Zaanan, A. [14 ]
McLachlan, S-A. [15 ]
Wu, H. [16 ]
Shi, J. [17 ]
Li, L. [18 ]
Yan, S. [19 ]
Yoon, H. [20 ]
机构：
[1] Hop St Louis, AP HP, Clin Dev, Paris, France
[2] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 5, Gastrointestinal Dept, Beijing 302 Hosp, Beijing, Peoples R China
[3] Natl Canc Ctr, Dept Gastrointestinal Med Oncol, Tokyo, Japan
[4] Christie NHS Fdn Trust, Clin Dev, Manchester, Lancs, England
[5] Nanjing Med Univ, Affiliated Hosp 1, Jiangsu Prov Hosp, Dept Oncol, Nanjing, Peoples R China
[6] Univ Ulsan, Asan Med Ctr, Oncol Dept, Seoul, South Korea
[7] Natl Canc Ctr Hosp East, Dept Gastroenterol & Gastrointestinal Oncol, Kashiwa, Chiba, Japan
[8] Maria Sklodowska Curie Natl Res Inst Oncol, Dept Radiotherapy & Oncol, Warsaw, Poland
[9] CHU Poitiers Jean Bernard Hop, Clin Dev, Poitiers, France
[10] UZ Gent Univ Hosp Ghent, Gastroenterol Dept, Ghent, Belgium
[11] Univ Hosp Gasthuisberg, Gastroenterol Digest Oncol, Leuven, Belgium
[12] Univ Leuven KU Leuven, Gastroenterol Digest Oncol, Leuven, Belgium
[13] Hosp Univ Miguel Servet, Med Oncol Dept, Zaragoza, Spain
[14] Hop Europeen Georges Pompidou, AP HP, Hepatogastroenterol & Digest Oncol, Paris, France
[15] GenesisCare St Vincents Hosp, Clin Dev, Melbourne, Vic, Australia
[16] BeiGene USA Inc, Stat & Data Sci, Ridgefield, NJ USA
[17] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Biomarker, Beijing, Peoples R China
[18] BeiGene Ltd, Clin Dev & Regulatory Off, Clin Dev, Beijing, Peoples R China
[19] BeiGene Beijing Co Ltd, Clin Dev, Beijing, Peoples R China
[20] Mayo Clin, Dept Oncol, Rochester, MN USA
来源：
ANNALS OF ONCOLOGY | 2024年 / 35卷
关键词：
D O I：
10.1016/j.annonc.2024.05.310
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
395MO
引用
收藏
页码：S159 / S159
页数：1
相关论文
共 50 条
  • [1] First-line (1L) tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 Japanese subgroup analysis with longer follow-up.
    Kojima, Takashi
    Ogata, Takashi
    Ishihara, Ryu
    Hara, Hiroki
    Sun, Tianmo
    Xu, Sheng
    Kato, Ken
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 420 - 420
  • [2] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs placebo (PBO) plus chemo as first-line (1L) treatment for advanced/metastatic esophageal squamous cell carcinoma (ESCC): RATIONALE-306 update
    Hubner, R.
    Xu, J.
    Kato, K.
    Raymond, E.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S. R.
    Kojima, T.
    Lin, C-Y.
    Gotovkin, E.
    Wyrwicz, L. S.
    Ishihara, R.
    Wu, H.
    Peng, Y.
    Wang, L.
    Li, L.
    Yoon, H.
    ANNALS OF ONCOLOGY, 2023, 34 : S853 - S853
  • [3] Randomized, global, phase 3 study of tislelizumab (TIS) plus chemotherapy (chemo) versus placebo (PBO) plus chemo as first-line (1L) treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Non-Asia subgroup.
    Raymond, Eric
    Hubner, Richard
    Gotovkin, Evgeny
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Pazo-Cid, Roberto
    Xu, Jianming
    Kato, Ken
    Tao, Aiyang
    Wang, Lei
    Peng, Yanyan
    Li, Liyun
    Yoon, Harry H.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 340 - 340
  • [4] Randomized, global, phase III study of tislelizumab (TIS) plus chemotherapy (chemo) vs chemo as first-line (1L) therapy for advanced or metastatic esophageal squamous cell carcinoma (ESCC) (RATIONALE-306): Asia subgroup
    Kato, K.
    Yoon, H.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Park, S. R.
    Ping, L.
    Jiang, Y.
    Zhang, J.
    Wu, X.
    Yao, Y.
    Shen, L.
    Kojima, T.
    Lin, C-Y.
    Wang, L.
    Tao, A.
    Peng, Y.
    Li, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S1458 - S1458
  • [5] Impact of tislelizumab plus chemotherapy versus placebo plus chemotherapy on patient-reported symptoms and overall survival (OS) by programmed death-ligand 1 (PD-L1) expression in advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of the RATIONALE-306 trial.
    Yoon, Harry H.
    Xu, Jianming
    Kato, Ken
    Pan, Yueyin
    Park, Sook Ryun
    Shen, Lin
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Barnes, Frederick
    Sun, Tianmo
    Barnes, Gisoo
    Victor, Timothy
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 366 - 366
  • [6] Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PDL1 biomarker analysis from RATIONALE-305
    Moehler, M.
    Oh, D-Y.
    Kato, K.
    Tabernero, J.
    Cruz-Correa, M.
    Wyrwicz, L. S.
    Pazo Cid, R. A.
    Cubillo, A.
    Evesque, L.
    Fornaro, L.
    Dotan, E.
    Morgan, C.
    Li, L.
    Xu, Y.
    Sheng, T.
    Yang, S.
    Hu, H.
    Xu, R-H.
    ANNALS OF ONCOLOGY, 2024, 35 : S160 - S161
  • [7] Response characteristics of tislelizumab (TIS) plus chemotherapy (chemo) in first-line (1L) treatment of locally advanced or metastatic esophageal squamous cell carcinoma (ESCC): A post hoc analysis of RATIONALE-306.
    Li, Yi
    Zhao, Chuanhua
    Liu, Rongrui
    Xu, Sheng
    Miao, Xiaojie
    Xu, Jianming
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (4_SUPPL) : 413 - 413
  • [8] RATIONALE-306: Randomized, global, placebo-controlled, double-blind phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (ESCC)
    Yoon, H.
    Kato, K.
    Raymond, E.
    Hubner, R.
    Shu, Y.
    Pan, Y.
    Jiang, Y.
    Zhang, J.
    Park, S.
    Kojima, T.
    Lin, C.
    Gotovkin, E.
    Wyrwicz, L.
    Ishihara, R.
    Li, L.
    Tao, A.
    Shi, J.
    Wang, L.
    Xu, J.
    ANNALS OF ONCOLOGY, 2022, 33 : S375 - S375
  • [9] Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced or metastatic oesophageal squamous cell carcinoma (RATIONALE-306): a global, randomised, placebo-controlled, phase 3 study
    Xu, Jianming
    Kato, Ken
    Raymond, Eric
    Hubner, Richard A.
    Shu, Yongqian
    Pan, Yueyin
    Park, Sook Ryun
    Ping, Lu
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Kojima, Takashi
    Gotovkin, Evgeny
    Ishihara, Ryu
    Wyrwicz, Lucjan
    Van Cutsem, Eric
    Jimenez-Fonseca, Paula
    Lin, Chen -Yuan
    Wang, Lei
    Shi, Jingwen
    Li, Liyun
    Yoon, Harry H.
    LANCET ONCOLOGY, 2023, 24 (05): : 483 - 495
  • [10] Randomized, global, phase 3 study of tislelizumab plus chemotherapy versus chemotherapy as first-line treatment for advanced or metastatic esophageal squamous cell carcinoma (RATIONALE-306): China subgroup analysis
    Shu, Yongqian
    Pan, Yueyin
    Lu, Ping
    Jiang, Yi
    Zhang, Jingdong
    Wu, Xiaohong
    Yao, Yuanhu
    Shen, Lin
    Ba, Yi
    He, Zhiyong
    Bai, Yuxian
    Chen, Jianhua
    Yu, Guohua
    Peng, Yanyan
    Wu, Hongqian
    Wang, Lei
    Li, Liyun
    Xu, Jianming
    CANCER RESEARCH, 2023, 83 (08)
12345